Advances in Nano-Emulsion Intranasal Delivery Systems for Neurotherapeutics like Depression
Megha Gautam, Nakul Gupta, Sarfaraz Alam, Shreyasi ThakurIntroduction:
Major Depressive Disorder (MDD) is a prevalent global mental health challenge with a multifactorial etiology, including genetic, environmental, and biochemical influences. Current pharmacological treatments, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), face limitations, including delayed therapeutic onset, systemic side effects, and poor permeability across the blood-brain barrier (BBB). To overcome these challenges, intranasal NE (NE) drug delivery systems have emerged as a promising approach for enhancing drug bioavailability and facilitating direct nose-to-brain transport.
Methods:
A comprehensive review of recent advancements in NE-based drug delivery for depression was conducted, focusing on formulation strategies, pharmacokinetic improvements, and therapeutic outcomes.
Results:
Recent advances in nanotechnology have positioned nanoemulsion (NE)-based intranasal delivery systems as a promising approach to enhance therapeutic outcomes in depression. These nanosystems, typically composed of lipid matrices, surfactants, and mucoadhesive agents, facilitate direct nose-to-brain transport while bypassing hepatic first-pass metabolism. Formulation studies have demonstrated that thermosensitive and mucoadhesive NEs significantly improve nasal retention, mucosal permeation, and controlled drug release, achieving high entrapment efficiency and favorable physicochemical stability. Optimized formulations have shown nanoscale particle sizes, appropriate zeta potential, and pH compatible with nasal physiology
Discussion:
Nanoemulsion-based intranasal delivery presents a promising strategy for treating MDD, offering physiological and pharmacological advantages over oral routes. By bypassing the blood-brain barrier, these systems enable rapid and targeted brain delivery, enhancing drug efficacy.
Conclusion:
Intranasal NE-based drug delivery presents a transformative strategy for treating MDD and other CNS disorders. By integrating nanoscale formulation approaches with tailored pharmacokinetics, this system offers improved drug efficacy, safety, and patient adherence. Future research should focus on optimizing formulations, ensuring long-term stability, and advancing clinical translation for broader CNS applications.